Dasatinib for the treatment of gastric cancer

ABSTRACT: Gastric cancer (GC) represents a major health problem, remaining the fifth most common type of cancer and the third leading cause of cancer-related death worldwide with only few targeted therapies available to date. The positive effect of kinase inhibitors on many different types of cancers has prompted the investigation of these compounds also in GC. In a screen of FDA-approved kinase inhibitors, dasatinib was found as a potent inhibitor of gastric cancer cells migration and invasion. In order to identify the kinases involved proteomics analysis was performed identifying SRC kinases, Ephrins and DDR1 as potential molecular targets.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Cell Culture

SUBMITTER: Stephanie Wilhelm  

LAB HEAD: Bernhard Kuster

PROVIDER: PXD012953 | Pride | 2020-05-26

REPOSITORIES: Pride